These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 1364158

  • 1. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT, Guillén CE, Sartorio GC, Soto RJ.
    Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
    [Abstract] [Full Text] [Related]

  • 2. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A, Ciechanek R.
    Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
    [Abstract] [Full Text] [Related]

  • 3. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seissler J.
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [Abstract] [Full Text] [Related]

  • 4. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE.
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [Abstract] [Full Text] [Related]

  • 5. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A, Janicki K, Pietura R, Janicka L.
    Ann Univ Mariae Curie Sklodowska Med; 2003 Dec; 58(1):248-53. PubMed ID: 15314994
    [Abstract] [Full Text] [Related]

  • 6. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T, Holle LH, Schroth HJ, Garth H.
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [Abstract] [Full Text] [Related]

  • 7. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M, Koizumi Y, Aizawa T, Yamada T, Takahashi Y, Watanabe T, Kamoi K.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [Abstract] [Full Text] [Related]

  • 8. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Nersita R, Iorio S, Amato G, Braverman LE, Roti E.
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [Abstract] [Full Text] [Related]

  • 9. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
    Zingrillo M, D'Aloiso L, Ghiggi MR, Di Cerbo A, Chiodini I, Torlontano M, Liuzzi A.
    Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E, Rosei EA.
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [Abstract] [Full Text] [Related]

  • 11. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
    Liu C, Duan Y, Wu X.
    Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
    [Abstract] [Full Text] [Related]

  • 12. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R.
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [Abstract] [Full Text] [Related]

  • 13. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].
    Komaki T, Sakata S, Nakamura S, Matsuda M, Kojima N, Takuno H, Miura K.
    Nihon Naibunpi Gakkai Zasshi; 1989 Jul 20; 65(7):627-39. PubMed ID: 2583311
    [Abstract] [Full Text] [Related]

  • 14. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
    Li J, Gao H, Xu L.
    Zhonghua Yi Xue Za Zhi; 1994 Apr 20; 74(4):218-20, 254-5. PubMed ID: 7922762
    [Abstract] [Full Text] [Related]

  • 15. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves' disease patients.
    Aleksić A, Aleksić Z, Stojanović M.
    Hell J Nucl Med; 2009 Apr 20; 12(2):146-50. PubMed ID: 19675869
    [Abstract] [Full Text] [Related]

  • 16. [TSH receptor antibodies as a recurrence index of Graves disease treated with antithyroid drugs].
    Arqueros MC, el Tamer E, el Tamer S, Houssay AB.
    Medicina (B Aires); 1991 Apr 20; 51(1):9-13. PubMed ID: 1921702
    [Abstract] [Full Text] [Related]

  • 17. [Thyrotropin receptor antibodies (TRAb) as a test of surgical treatment effectiveness in Graves-Basedow's diseases].
    Bojarska-Szmygin A, Ciechanek R, Jezierska B, Zaorska-Rajca J.
    Pol Merkur Lekarski; 2002 Sep 20; 13(75):196-9. PubMed ID: 12474569
    [Abstract] [Full Text] [Related]

  • 18. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW.
    Clin Endocrinol (Oxf); 2004 Jun 20; 60(6):676-81. PubMed ID: 15163329
    [Abstract] [Full Text] [Related]

  • 19. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE, Basedow Study Group.
    Thyroid; 2005 Sep 20; 15(9):1047-54. PubMed ID: 16187913
    [Abstract] [Full Text] [Related]

  • 20. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers.
    Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, Salerno M, Delvecchio M, Peroni E, Pistorio A, Corrias A.
    J Pediatr; 2014 May 20; 164(5):1189-1194.e1. PubMed ID: 24518168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.